{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:58:03Z","timestamp":1783465083301,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1784,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan combines renin\u2013angiotensin\u2013aldosterone system inhibition with amplification of natriuretic peptides. In addition to well-described effects, natriuretic peptides exert direct effects on pulmonary vasculature. The effect of sacubitril\/valsartan on pulmonary artery pressure (PAP) has not been fully defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This was a retrospective case-series of PAP changes following transition from angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) to sacubitril\/valsartan in patients with heart failure reduced ejection fraction and a previously implanted CardioMEMS\u2122 sensor. Pre-sacubitril\/valsartan and post-sacubitril\/valsartan PAPs were compared for each patient by examining averaged consecutive daily pressure readings from 1 to 5 days before and after sacubitril\/valsartan exposure. PAP changes were also compared between patients based on elevated trans-pulmonary gradients (trans-pulmonary gradient \u2265 12 mmHg) at time of CardioMEMS\u2122 sensor implantation. The cohort included 18 patients, 72% male, mean age 60.1 \u00b1 13.6 years. There was a significant decrease in PAPs associated with transition from ACEI\/ARB to sacubitril\/valsartan. The median (interquartile range) pre-treatment and post-treatment change in mean, systolic and diastolic PAPs were \u22123.6 (\u22129.8, \u22120.7) mmHg (P &amp;lt; 0.001), \u22126.5 (\u221215.0, \u22122.0) mmHg (P = 0.001), and \u22122.5 (\u22125.7, \u22120.7) (P = 0.001), respectively. The decrease in PAPs was independent of trans-pulmonary gradient (F(1,16) = 0.49, P = 0.49).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective case series, transition from ACEI\/ARB to sacubitril\/valsartan was associated with an early and significant decrease in PAPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13225","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T01:50:30Z","timestamp":1612144230000},"page":"1706-1710","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Acute Pulmonary Pressure Change After Transition to Sacubitril\/Valsartan in Patients with Heart Failure Reduced Ejection Fraction"],"prefix":"10.1093","volume":"8","author":[{"given":"Jeffrey S.","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Havakuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]},{"name":"Department of Cardiology, Tel Aviv Medical Center, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"McLeod","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Einstein Center for Heart and Vascular Care, Albert Einstein College of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi Yan","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shavelle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"Division of Cardiology, RHJ Department of Veterans Affairs Medical Center, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Elkayam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keck School of Medicine of the University of Southern California (USC) , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-2526","authenticated-orcid":false,"given":"Luanda P.","family":"Grazette","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Miller School of Medicine, University of Miami , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,31]]},"reference":[{"key":"2026012115072312800_ehf213225-bib-0001","doi-asserted-by":"crossref","first-page":"40","DOI":"10.15420\/cfr.2016:1:1","article-title":"The mechanism of action of LCZ696","volume":"2","author":"Menendez","year":"2016","journal-title":"Card Fail Rev"},{"key":"2026012115072312800_ehf213225-bib-0002","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115072312800_ehf213225-bib-0003","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, angiotensin II receptor\u2013neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am J Hypertens"},{"key":"2026012115072312800_ehf213225-bib-0004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0306-3623(96)00275-3","article-title":"Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds","volume":"28","author":"Arjona","year":"1997","journal-title":"Gen Pharmacol"},{"key":"2026012115072312800_ehf213225-bib-0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.CIR.99.5.605","article-title":"NPR-A\u2013deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension","volume":"99","author":"Zhao","year":"1999","journal-title":"Circulation"},{"key":"2026012115072312800_ehf213225-bib-0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.healun.2014.04.014","article-title":"Pulmonary hypertension related to left heart disease: insight from a wireless implantable hemodynamic monitor","volume":"34","author":"Benza","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"2026012115072312800_ehf213225-bib-0007","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115072312800_ehf213225-bib-0008","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/0735-1097(95)00587-0","article-title":"Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival","volume":"27","author":"Rickenbacher","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2026012115072312800_ehf213225-bib-0009","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008268","article-title":"Combined angiotensin receptor\u2013neprilysin inhibitors improve cardiac and vascular function via increased NO bioavailability in heart failure","volume":"7","author":"Trivedi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012115072312800_ehf213225-bib-0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor\u2013neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115072312800_ehf213225-bib-0011","first-page":"108","article-title":"Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients","volume":"7","author":"Almufleh","year":"2017","journal-title":"Am J Cardiovasc Dis"},{"key":"2026012115072312800_ehf213225-bib-0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5603\/ARM.2018.0042","article-title":"Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease","volume":"86","author":"Liczek","year":"2018","journal-title":"Adv Respir Med"},{"key":"2026012115072312800_ehf213225-bib-0013","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2019.06.065","article-title":"Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure","volume":"293","author":"Andersen","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026012115072312800_ehf213225-bib-0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006696","article-title":"Angiotensin receptor\u2013neprilysin inhibitor therapy reverses pulmonary hypertension in end-stage heart failure patients awaiting transplantation","volume":"13","author":"Zern","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026012115072312800_ehf213225-bib-0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/bph.14621","article-title":"Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial","volume":"176","author":"Hobbs","year":"2019","journal-title":"Br J Pharmacol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13225","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13225","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1706\/65926376\/eschf_8_2_1706.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/2\/1706\/65926376\/eschf_8_2_1706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:09:08Z","timestamp":1769026148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/2\/1706\/8381841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,31]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,31]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13225","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,1,31]]},"assertion":[{"value":"2020-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}